SCHEMBL3096784

SCHEMBL3096784

CCN(C(=O)C(Cc1cnn(Cc2ccccc2)c1)C(=O)NS(=O)(=O)/C=C/c1ccccc1)c1cccc2ccccc12

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 3/20 0.34
GAA P10253 1/20 0.34
ALDH1A1 P00352 7/20 0.33
KDM4E B2RXH2 3/20 0.33
ACACB O00763 1/20 0.33
TSHR P16473 1/20 0.33
ITK Q08881 1/20 0.33
HDAC2 Q92769 1/20 0.32
LMNA P02545 3/20 0.32
MAPT P10636 2/20 0.32
HTT P42858 2/20 0.32
MEN1 O00255 1/20 0.32
HPGD P15428 1/20 0.32
HDAC1 Q13547 1/20 0.32
F2 P00734 1/20 0.32
TP53 P04637 1/20 0.31
SIGMAR1 Q99720 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3096794 1.00 L3MBTL1 (0.36) L3MBTL1KMT2AGAAALDH1A1KDM4E
SCHEMBL3092554 0.89 HDAC2 (0.35) GAAALDH1A1ACACBITKHDAC2
SCHEMBL3092559 0.89 HDAC2 (0.35) GAAALDH1A1ACACBITKHDAC2
SCHEMBL3096711 0.88 SCD (0.34) ALDH1A1ACACBITKHDAC2HTT
SCHEMBL3096719 0.88 SCD (0.34) ALDH1A1ACACBITKHDAC2HTT
SCHEMBL3103969 0.86 HDAC2 (0.36) L3MBTL1GAAALDH1A1ACACBITK
SCHEMBL3103975 0.86 HDAC2 (0.36) L3MBTL1GAAALDH1A1ACACBITK
SCHEMBL3093137 0.86 ALDH1A1 (0.34) ALDH1A1KDM4EACACBITKHDAC2
SCHEMBL3093130 0.86 ALDH1A1 (0.34) ALDH1A1KDM4EACACBITKHDAC2
SCHEMBL3093150 0.85 ACACB (0.33) GAAALDH1A1KDM4EACACBITK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2172450-B9 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2014-10-08 EP disclosed
EP-2172450-B1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORP (JP) 2013-10-16 EP disclosed
US-8461209-B2 Malonic acid sulfonamide derivative and pharmaceutical use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-11 US disclosed
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-09 US disclosed
EP-2172450-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2010-04-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228026-A1 NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF REN, AGTR2, AGTR1 L3MBTL1 4273/4885KMT2A 1948/4885GAA 272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.